Chinese price cuts aimed at patented drugs hit multinationals
This article was originally published in Scrip
Executive Summary
Following the last reductions in March, China's National Development and Reform Commission (NDRC) has initiated a new round of price cuts, targeting products containing 82 active ingredients for endocrine, hormonal and CNS disorders.